Why the study?
Although analytical interferences affecting hs-cTn reporting are uncommon, not all hs-cTn assays share the same design or validation, prompting evaluation after an initial case of discrepant hs-cTnI results.
Does the Ortho Clinical Diagnostics hs-cTnI assay misclassify myocardial injury compared to the Abbott Diagnostics assay in patients with an acute phase response?
Population
Patients being assessed for myocardial injury, particularly those with an acute phase response
Comparison
Ortho Clinical Diagnostics hs-cTnI assay vs Abbott Diagnostics hs-cTnI assay
Authors
Loading...
The Ortho Clinical Diagnostics hs-cTnI assay may yield falsely elevated and non-reproducible results in patients with an acute phase response, warranting caution in its clinical interpretation.
Does the Ortho Clinical Diagnostics hs-cTnI assay misclassify myocardial injury compared to the Abbott Diagnostics assay in patients with an acute phase response?
The Ortho Clinical Diagnostics hs-cTnI assay may yield falsely elevated and non-reproducible results in patients with an acute phase response, warranting caution in its clinical interpretation.
Kavsak et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: